NCT00748150View on ClinicalTrials.gov

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Influenza
Interventions
BIOLOGICAL

Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009

1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009

Trial Locations (1)

IP309QU

The Health Centre, Heath Road, Woolpit, Bury Saint Edmunds

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY